tralokinumab

Home
Ligands
tralokinumab

GtoPdb Ligand ID: 8001

Synonyms: Adbry® | Adtralza® | BAK1.1 [2] | CAT-354 [2] | tralokinumab-ldrm

tralokinumab is an approved drug (EMA & FDA (2021))

Comment: Tralokinumab is a monoclonal antibody directed against interleukin 13 (IL-13), a cytokine secreted by T helper cells, and which is a central mediator of the physiological changes induced by allergic inflammatory reactions [4] Binding affinity of tralokinumab was optimised (aka affinity maturation) using an in vitro ribosome display technology [2].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

No information available.

No information available.

Summary of Clinical Use
Tralokinumab reached Phase 3 clinical trials for uncontrolled asthma, and atopic dermatitis, and Phase 2 for alopecia areata. Click here to link to ClinicalTrials.gov's listing of Phase 3 tralokinumab trials. In addition, Phase 2 trials are investigating tralokinumab as a treatment for idiopathic pulmonary fibrosis (IPF, NCT01629667 and NCT02036580). Business reports online indicate that AstraZeneca have discontinued tralokinumab development foa asthma as it showed no benefit over placebo in their STRATOS 2 and TROPOS late-stage asthma trials [1]. The EMA approved LEO Pharma's tralokinumab product Adtralza® in July 2021, as a treatment for severe atopic dermatitis that cannot be controlled by topical drugs. FDA approval for this indication followed at the end of 2021.

Summary of Clinical Use

Tralokinumab reached Phase 3 clinical trials for uncontrolled asthma, and atopic dermatitis, and Phase 2 for alopecia areata. Click here to link to ClinicalTrials.gov's listing of Phase 3 tralokinumab trials. In addition, Phase 2 trials are investigating tralokinumab as a treatment for idiopathic pulmonary fibrosis (IPF, NCT01629667 and NCT02036580). Business reports online indicate that AstraZeneca have discontinued tralokinumab development foa asthma as it showed no benefit over placebo in their STRATOS 2 and TROPOS late-stage asthma trials [1].
The EMA approved LEO Pharma's tralokinumab product Adtralza® in July 2021, as a treatment for severe atopic dermatitis that cannot be controlled by topical drugs. FDA approval for this indication followed at the end of 2021.

Mechanism Of Action and Pharmacodynamic Effects
IL-13 induces airway hyperresponsiveness, goblet cell metaplasia and mucus hypersecretion in allergic lung disease such as asthma [3]. These changes contribute to airway obstruction. Tralokinumab was designed to neutralise circulating IL-13, thereby reducing disease symptoms.

Mechanism Of Action and Pharmacodynamic Effects

IL-13 induces airway hyperresponsiveness, goblet cell metaplasia and mucus hypersecretion in allergic lung disease such as asthma [3]. These changes contribute to airway obstruction. Tralokinumab was designed to neutralise circulating IL-13, thereby reducing disease symptoms.

External links
For extended ADME data see the following: European Medicines Agency (EMA)

External links

For extended ADME data see the following:

European Medicines Agency (EMA)